PD168368 is a potent, competitive, and selective neuromedin B receptor (NMB-R) antagonist with Ki of 15 nM, IC50 of 96 nM.
PD 168368 also is a mixed FPR1/FPR2/FPR3 agonist with EC50 of 0.57, 0.24, and 2.7 nM, respectively.
PD168368 is highly active and stimulated [Ca2+]I release in human neutrophils with EC50 values in the nanomolar range.
PD168368 suppresses migration and invasion of the human breast cancer cell line MDA-MB-231.
PD168368 reduces epithelial-mesenchymal transition (EMT) of breast cancer cells by E-cadherin upregulation and vimentin downregulation.
PD168368 suppresses the activation of mTOR/p70S6K/4EBP1 and AKT/GSK-3β pathways in breast cancer cells.
PD168368 potently inhibits in vivo metastasis of breast cancer.
